Research never stops

Structure-based drug design

Guided by high-quality data, structure-based drug design (“SBDD”) at Evotec distils information into hypothesis-driven medicinal chemistry. By minimising unnecessary and wasteful compound synthesis, productivity is increased and chemistry teams are able to focus on an efficient path to the final drug.

Evotec has a comprehensive SBDD platform comprising state-of-the-art capabilities in: 

  • Computational chemistry
  • Protein production
  • X-ray crystallography
  • Biophysical screening tools such as nuclear magnetic resonance spectrometry (“NMR”), surface plasmon resonance spectrometry (“SPR”), mass spectrometry (“MS”) and isothermal titration calorimetry (“ITC”)

The SBDD platform at Evotec includes a comprehensive fragment-based drug discovery (“FBDD”) platform. Sensitive screening techniques, such as the FCS+plus (proprietary to Evotec) or NMR, SPR or MS combined with specifically selected fragment compound collections, identify diverse, active low molecular weight fragments providing multiple highly efficient starting points for chemical optimisation.

For more detailed information, please click on this link or contact us at

Structure-based drug design